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Abstract
Adenomyosis is a benign uterine disorder in which endometrial glands and
stroma are pathologically demonstrated in the uterine myometrium and it is
considered a specific entity in the PALM-COEIN FIGO (polyp;
adenomyosis; leiomyoma; malignancy and hyperplasia; coagulopathy;
ovulatory dysfunction; endometrial; iatrogenic; and not yet classified –
International Federation of Gynecology and Obstetrics) classification of
causes of abnormal uterine bleeding (AUB). Although it has always been
considered the classic condition of multiparous women over 40 years old
who have pain and heavy menstrual bleeding, diagnosed at hysterectomy,
the epidemiological scenario has completely changed. Adenomyosis is
increasingly identified in young women with pain, AUB, infertility, or no
symptoms by using imaging techniques such as transvaginal ultrasound
and magnetic resonance. However, there is no agreement on the definition
and classification of adenomyotic lesions from both the histopathology and
the imaging point of view, and the diagnosis remains difficult and unclear. A
uniform and shared reporting system needs to be implemented in order to
improve our understanding on imaging features, their relationship with
pathogenic theories, and their importance in terms of clinical symptoms and
response to treatment. In fact, adenomyosis pathogenesis remains elusive
and not a single theory can explain all of the different phenotypes of the
disease. Furthermore, adenomyosis often coexists with other gynecological
conditions, such as endometriosis and uterine fibroids, increasing the
heterogeneity of available data. Treatment requires a lifelong management
plan as the disease has a negative impact on quality of life in terms of
menstrual symptoms, fertility, and pregnancy outcome and has a high risk
of miscarriage and obstetric complications.
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Introduction
Adenomyosis is a benign uterine disorder in which endometrial 
glands and stroma are pathologically demonstrated in the 
myometrium1. Women affected by adenomyosis may present with 
abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, 
or infertility but one third of them are asymptomatic2. For many 
years, adenomyosis has remained a histopathological diagnosis 
made after hysterectomy in perimenopausal women with heavy 
menstrual bleeding (HMB) or pelvic pain3. Over the last decade, 
adenomyosis has also become a condition identified in young 
fertile-age women4 thanks to the recent advancements in 
imaging techniques, even though a shared definition and classi-
fication are still lacking5. Despite the improvement of diagnostic 
tools, the awareness of the condition is still poor. Furthermore, 
in some patients, adenomyosis coexists with other gynecological 
conditions, such as endometriosis and uterine fibroids6. The 
physio-pathological mechanisms, involving sex steroid hormone 
aberrations, inflammation, fibrosis, and neuroangiogenesis, are 
not fully understood7. Regarding the current management of 
adenomyosis, there are no international guidelines to follow for 
surgical or medical treatment of adenomyosis8 and this will 
be of utmost importance in the future as the disease requires a 
lifelong management plan, including pain and bleeding control, 
fertility preservation, and pregnancy outcome.
Pathogenesis
The pathogenic mechanisms involved in adenomyosis need to 
be fully elucidated, but in the last decade an increasing number 
of studies have shown that sex steroid hormone receptors, 
inflammatory molecules, extracellular matrix enzymes, growth 
factors, and neuroangiogenic factors play a major role7,9,10.
According to the most common theory, adenomyosis results from 
the invagination of basalis endometrium into the myometrium 
through an altered or interrupted junctional zone (JZ)7,11, which 
represents a highly specialized hormone-responsive structure 
located in the inner third of the myometrium12. Molecular 
alterations in eutopic endometrium seem to contribute to migra-
tion and survival of ectopic endometrial implants beyond the 
myometrial interface13. Even though alterations in apoptosis, 
steroid hormone responsiveness, and extracellular matrix path-
ways have been found in both adenomyotic lesions and eutopic 
endometrium, the underlying mechanisms need to be further 
evaluated. In addition, the role of tissue injury and repair (TIAR) 
as the primary mechanism for myometrial invasion has been 
hypothesized6. Chronic peristaltic myometrial contractions may 
induce continuous microtrauma to the JZ, causing inflamma-
tion which in turn promotes local increased estrogen production, 
inducing a vicious cycle. A positive feedback mechanism is 
generated, and chronic hyperperistalsis in the JZ promotes 
repeated cycles of autotraumatization14. Thus, the TIAR theory, 
stressing the importance of tissue damage to the endometrial– 
myometrial interface, supports the common understanding that 
adenomyosis is associated with multiparity, previous cesarean 
section, and prior uterine surgery11.
An alternative pathogenic theory of adenomyosis proposes 
that the disease arises de novo from metaplasia of embryonic or 
adult stem cell in the myometrium15. Intramyometrial embryonic 
pluripotent Müllerian remnants may undergo metaplastic changes 
in the adult uterine wall, leading to the establishment of de novo 
ectopic endometrial tissue within the myometrial wall, as adeno-
myotic foci. However, the hypothesis of adult endometrial and 
stromal stem cell differentiation whenever they are deposited 
in the myometrium after retrograde menstruation should also 
be taken into account11,16. Accordingly, Chapron et al. described 
“from outside to inside invasion” theory, hypothesizing the 
migration of ectopic endometrial cells from posterior endome-
triosis nodules into the myometrium17. This theory was supported 
by the high prevalence of posterior focal adenomyosis of the 
outer myometrium (FOAM) found in patients with deep infiltrat-
ing endometriosis (DIE) nodules in the posterior compartment, 
diagnosed by magnetic resonance imaging (MRI)17. After 
retrograde menstruation, ectopic endometrial cells may have the 
potential to infiltrate not only pelvic organs but also the uterine 
walls. Less clear is the explanation for the 50% association of 
anterior FOAM shown in bladder DIE18. The intraperitoneal 
seeding of endometrial cells after menstruation may cause 
invasion of the vesicouterine pouch, generating both a bladder 
nodule and anterior FOAM through a trans-serosa invading 
process. Nevertheless, the pathogenesis of adenomyosis is still 
unclear and cannot be understood by only a unique theory since 
the phenotypes are heterogeneous and not clearly defined.
Epidemiology
Historically, adenomyosis has been identified as a pathological 
entity from histological reports after hysterectomy. However, 
currently, only a small group of women undergo non-con-
servative surgical treatments for adenomyosis; thus, a realistic 
epidemiological background cannot be established from his-
topathology. Furthermore, the introduction of new medical 
compounds and surgical techniques has allowed clinicians to 
conservatively treat the disease. Thus, the epidemiological 
scenario has changed, and although the most common risk 
factor profile19 included age of more than 40 years, multiparity, 
prior cesarean section, or uterine surgery19,20, the disease is 
increasingly diagnosed in young women4, in infertility patients21, 
or in those with pain or AUB or both22. In regard to AUB, in 
fact, adenomyosis is considered a specific entity in the PALM-
COEIN FIGO (polyp; adenomyosis; leiomyoma; malignancy and 
hyperplasia; coagulopathy; ovulatory dysfunction; endometrial; 
iatrogenic; and not yet classified – International Federation of 
Gynecology and Obstetrics) classification23,24 and it is strictly 
associated with HMB22. However, it should also be considered 
that one third of patients with adenomyosis are asymptomatic2. 
In women undergoing assisted reproductive technologies (ARTs), 
the prevalence of adenomyosis is 20% to 25%21, whereas in 
those with a history of endometriosis, the percentage is widely 
variable, ranging from 20% to 80%25,26. Data from ultrasound 
units show a 20.9% prevalence of sonographic signs of adenom-
yosis in the general population27, whereas the figures range from 
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10% to 35% in histological reports after hysterectomy28,29. 
However, uniform diagnostic criteria, in both histopathology and 
imaging, are needed in order to standardize the diagnosis and 
to have reliable updated figures.
Definition and diagnosis of adenomyosis
Histology
The gold standard to make the final diagnosis of adenomyo-
sis has always been considered histological examination of 
hysterectomy specimens23. So, in 2009, Weiss et al. declared 
that adenomyosis was an incidental finding in women undergo-
ing hysterectomy and not the source of their symptoms30. The 
condition is commonly described as the presence of endometrial 
glands and stroma located deep within the myometrium, associ-
ated with smooth muscle hyperplasia31. This is due to the inva-
sion of myometrium by basal glands and stroma with destruction 
of normal myometrium architecture32. However, the frequency 
of adenomyosis diagnosis can range widely among different 
pathologists as there are no uniform criteria regarding depth 
of invasion and number of foci to make a diagnosis, especially 
when disease is not diffuse. In previous papers, an invasion more 
than one third thickness of the uterine myometrium has been 
considered to make a diagnosis, whereas in others a myometrial 
invasion greater than 4 mm was diagnostic for adenomyosis33–35. 
Regarding histological classification, adenomyosis is defined 
as focal when circumscribed nodular aggregates of endome-
trial glands and stroma are surrounded by normal myometrium. 
Conversely, an adenomyoma is identified when the ectopic 
endometrial tissue within the myometrium is surrounded by 
hypertrophic myometrium. In diffuse adenomyosis, endometrial 
glands and stroma are recognized throughout the myometrium.
However, the available criteria do not consider potential dif-
ferent morphological appearance of ectopic cells according to 
cellular differentiation stage and menstrual cycle or responsive-
ness to hormonal drugs. In addition, results from histopathological 
studies are biased by the fact that in those cases all women 
underwent a non-conservative treatment; thus, this does not repre-
sent the entire population of adenomyotic patients or all possible 
phenotypes.
Imaging
The development of imaging techniques, such as MRI and 
transvaginal ultrasonography (TVUS), has allowed clinicians to 
make a non-invasive diagnosis of adenomyosis in women also 
undergoing conservative treatments, identifying different phe-
notypes of the disease. After some attempts of histological clas-
sification36, Kishi et al. (in 2012) classified adenomyosis in 
four subtypes according to MRI lesion localization in the inner 
or outer myometrium: intrinsic, extrinsic, intramural, and inde-
terminate37. In 2014, Grimbizis et al. proposed a clinical histo-
logical classification system, identifying diffuse, focal, and cystic 
adenomyosis38. More recently, Bazot and Daraï proposed three 
subtypes—internal, external adenomyosis, and adenomyomas—
according to MRI features39. However, a shared classification 
system has not been developed yet as further research is needed 
in order to better understand the physiopathology of adenomyo-
sis, its onset and progression, and the interpretation of imaging 
signs according to the pathogenic theories.
Transvaginal ultrasound sonography. TVUS represents the 
first-line imaging technique to diagnose adenomyosis as it is 
widely available, relatively inexpensive, and very accurate if 
performed by expert sonographers. The sensitivity of TVUS to 
detect adenomyosis ranges from 65% to 81%, and specificity 
ranges from 65% to 100%. A recent meta-analysis, pooling results 
from eight studies, showed that two-dimensional TVUS has a 
sensitivity and specificity of 83.8% and 63.9%, respectively, and 
that for three-dimensional TVUS, pooled sensitivity and spe-
cificity for all combined imaging characteristics are 88.9% and 
56.0%, respectively40. Recently, a uniform standardized reporting 
system of ultrasound findings of adenomyosis was developed 
by using the Morphological Uterus Sonographic Assessment 
(MUSA) criteria41. According to those criteria, the typical ultra-
sound features to consider in order to make a diagnosis of aden-
omyosis are described as follows: asymmetrical thickening of 
uterine walls, intramyometrial cysts or hyperechoic islands (or 
both), fan-shaped shadowing of the myometrium, myometrial 
echogenic subendometrial lines and buds, translesional vascularity, 
and irregular or interrupted JZ. However, there is little available 
evidence linking the ultrasound features with histopathology42,43, 
even though the different sonographic characteristics may be 
explained by the relative proportion of endometrial glandular 
structures, endometrial stroma, and hypertrophic muscle elements.
The new reporting system of adenomyosis, proposed by Van den 
Bosch and de Bruijn et al., includes the description of disease 
location (anterior, posterior, left lateral, right lateral, and fun-
dal), classification of the lesions as focal or diffuse, presence or 
absence of intralesional cysts, myometrial layer involvement (JZ, 
myometrium, and serosal involvement), disease extent (<25%, 
25%–50%, and >50% of uterine volume affected by adenomyosis), 
and lesion size44. This system would help to standardize the 
ultrasound description of adenomyosis; however, it has some 
limitations to be fully implemented in clinical practice. For 
example, the measurement of uterine volume affected by the dis-
ease is difficult to be objectively evaluated. Furthermore, the 
system needs to be validated and to be correlated with clinical 
findings and fertility outcomes in further studies. In fact, another 
major problem is the definition of severity of the disease and 
the identification of those features that make clinically more 
severe adenomyosis. Previously, Naftalin et al. showed a positive 
correlation between the number of ultrasound features of ade-
nomyosis and the severity of menstrual pain, but there is no 
available evidence in which features are relevant from a clinical 
perspective45. Recently, a scoring system to define the severity 
of adenomyosis was proposed46; similarly, Tellum et al. devel-
oped a clinical prediction model to identify the disease by using 
the most relevant features47. However, those models need to be 
externally validated and more evidence should support their 
reliability.
Magnetic resonance imaging. MRI diagnosis of adenomyo-
sis is essentially linked to the thickening of the JZ, but it also 
includes direct and indirect signs of the presence of endometrial 
glands within the myometrium and smooth muscle cell hyper-
trophy48. Typical adenomyosis appears as an ill-demarcated low-
signal-intensity area on T2-weighted images, representing the 
smooth muscle hyperplasia and the heterotopic endometrial tissue. 
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T2-weighted sequences play a key role for MRI diagnosis of 
adenomyosis since they highlight the JZ, which has commonly 
increased thickness49. Furthermore, on T2-weighted MRI, small 
high-signal-intensity areas refer to ectopic endometrium and 
also small intramyometrial cysts may be detected. However, 
T1-weighted sequences also contribute to the diagnosis as they are 
useful in identifying high-signal-intensity foci representing areas 
of hemorrhage49. The detection of bright hemorrhagic foci has a 
high positive predictive value (95%) for the diagnosis of adeno-
myosis but a low sensitivity (47.5%)31. The common appearance 
of adenomyosis is an enlarged, asymmetric uterus, where ade-
nomyotic tissue is located mainly in the posterior wall or at the 
fundus. The most frequent finding to diagnose adenomyosis is the 
thickening of JZ, and several criteria have been proposed (JZ of at 
least 8–12 mm, the maximum JZ/total myometrium ratio of over 
40%, and a difference between the maximum and the minimum 
thickness of greater than 5 mm); however, a thickness exceed-
ing 12 mm seems to be highly predictive of adenomyosis31,50. 
Nevertheless, results are controversial as JZ may change on the 
basis of hormonal status (postmenopausal condition and use of 
hormonal contraception) and phase of menstrual cycle51. During 
menstruation, the uterus may present with a marked thicken-
ing of the JZ, mimicking adenomyosis; thus, MRI evaluations 
should preferably be performed in the late proliferative phase. 
Furthermore, a common pitfall to consider is caused by transient 
uterine contractions that can mimic either T2-weighted hypoin-
tense bands perpendicular to the JZ or focal thickening of the 
JZ52. In those cases, the repetition of MRI acquisition may help 
to differentiate a physiological condition from adenomyosis53.
A JZ of less than 8 mm generally allows clinicians to exclude the 
presence of adenomyosis42, whereas a measurement between 8 
and 12 mm identifies the condition of adenomyosis if other cri-
teria are present, such as maximal JZ thickness–to–myometrium 
thickness ratio over 40% or a relative thickening of the JZ in 
a localized area54. Another criterion to be considered is a differ-
ence between the maximum and the minimum thickness of the JZ 
measuring more than 5 mm54. However, adenomyosis may also be 
identified in the case of a poorly defined JZ or in the presence of 
linear striations of high T2 signal radiating from the endometrial 
zona basalis into the myometrium.
According to the most recent review on imaging of adenomyo-
sis, MRI has a pooled sensitivity of 0.77, specificity of 0.89, 
positive likelihood ratio of 6.5, and negative likelihood ratio of 0.2 
for all subtypes, showing better results compared with those of 
TVUS39. However, MRI should be considered a second-line imag-
ing technique and should be performed by expert radiologists.
Coexistence with other gynecological conditions
Adenomyosis frequently coexists with other gynecological dis-
eases, such as endometriosis25 and uterine fibroids55,56. In 15% 
to 57% of cases, uterine leiomyomas and adenomyosis coex-
ist in the same uterus and women with both conditions are more 
likely to experience pelvic pain57. Results from a case-control 
study on women undergoing hysterectomy showed that women 
with leiomyoma and adenomyosis were more likely to report 
dysmenorrhea, dyspareunia, and non-cyclic pelvic pain compared 
with women with leiomyomas only3,57,58.
Adenomyosis and endometriosis share a number of features, so 
that for many years adenomyosis has been called endometriosis 
interna. Nevertheless, they are considered two different entities 
because of specific pathogenic pathways and clinical presenta-
tion, although they often coexist in the same patients. Contro-
versial results are available from a surgical dataset showing that 
adenomyosis prevalence in women with endometriosis ranges 
from 20% to 80%25,26. Besides, on ultrasound pre-operative 
assessment, 47.8% of patients undergoing surgery for DIE were 
affected by adenomyosis, and in those affected by both condi-
tions, the surgical treatment was not as effective in treating pain 
as it was in those with only endometriosis59. Furthermore, DIE 
phenotype was also shown to be associated with a specific form 
of focal adenomyosis located in the outer myometrium17. How-
ever, larger samples of pre-operative cases are needed in order 
to better estimate the prevalence of gynecological comorbidities.
Impact on fertility
Adenomyosis has been considered the typical uterine condition 
of multiparous women, although an increasing amount of evi-
dence suggests an association with infertility and reproductive 
failure60–63. In a recent cross-sectional study on infertile women, 
adenomyosis prevalence were 24.4% in women at least 40 years 
old and 22% in women less than 40 years old. This percentage 
increased to 38.2% in cases of recurrent pregnancy loss and to 
34.7% in previous ART failure21.
Currently, infertility is considered one of the possible clini-
cal presentations of adenomyosis and several theories have been 
proposed to explain the underlying mechanisms7. Abnormal utero-
tubal transport seems to be an important mechanism leading to 
infertility and is due to anatomical distortion of the uterine cav-
ity but also to disturbed uterine peristalsis and sperm transport64. 
The inner myometrium and, in particular, the JZ present with 
dysfunctional hyperperistalsis and increased intrauterine pres-
sure. In addition, in the presence of adenomyosis, ultrastructural 
myometrial abnormalities cause a disturbance in normal myo-
cyte contractility with subsequent loss of normal rhythmic 
contraction65.
In infertile women with adenomyosis, eutopic endometrium 
shows a wide variety of molecular alterations, causing an altered 
receptivity13,66. This includes altered sex steroid hormone path-
way, increased inflammatory markers and oxidative stress, 
reduced expression of implantation markers, lack of expression of 
adhesion molecules, and altered function of the gene for embry-
onic development (HOXA 10 gene), causing an impairment of 
implantation in women with adenomyosis7.
There are no available studies on natural conception in adeno-
myosis, but several papers evaluated the effect of adenomyo-
sis in women undergoing ART or in those surgically treated for 
DIE67, and results are controversial. The meta-analysis published 
by Vercellini et al. in 201460 reported rates of miscarriages of 31% 
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in women with adenomyosis and 14.1% in non-affected women 
(relative risk (RR) 2.12, 95% confidence interval (CI) 1.20–
3.75)60. On the contrary, a case-control study in a group of women 
undergoing in vitro fertilization (IVF) showed that implantation 
rate was not significantly impaired in those diagnosed with 
adenomyosis at TVUS, but asymptomatic for AUB, compared 
to those not affected by the disease68. On the contrary, Mavrelos 
et al.69, in a multicenter prospective study, showed that the esti-
mated probability of clinical pregnancy decreased from 42.7% in 
women with no adenomyosis to 22.9% in those with four and 
13.0% in those with all seven ultrasound features of adenomyo-
sis. This suggests that the severity of the condition, expressed as 
a number of morphological features on ultrasound, worsens the 
reproductive outcome. Results from the most recent systematic 
review and meta-analysis on IVF treatment outcomes in adeno-
myosis, including 11 studies and 519 patients with TVUS or 
MRI diagnosis of adenomyosis, confirmed the detrimental effect of 
the uterine disease on reproductive outcome61. Rates of implanta-
tion, clinical pregnancy per cycle, clinical pregnancy per embryo 
transfer, ongoing pregnancy, and live-birth rate among women 
with adenomyosis were significantly reduced, whereas miscar-
riage rate was increased. The study also demonstrated that a pre-
IVF treatment with the use of gonadotropin-releasing hormone 
analogue (GnRHa) down-regulation may be beneficial to the 
pregnancy rate61.
Concerning the association between endometriosis and adeno-
myosis and fertility, results from a systematic review and meta- 
analysis published in 2014 on women after surgery for rectovagi-
nal and colorectal endometriosis reported a 68% reduction in the 
likelihood of pregnancy in women who wanted to become preg-
nant70. In a recent retrospective cohort of women undergoing 
IVF, the presence of adenomyosis affected clinical pregnancy rate, 
live-birth rate and miscarriage rate. In particular, compared with 
women with endometriosis alone, those affected by adenomyosis 
had a significantly lower clinical pregnancy rate (26.4% versus 
12.5%) and live-birth rate (26.4% versus 12.5%). Similar results 
were reported in women with endometriosis and adenomyosis71.
All of this evidence supported a negative effect of adenomyosis 
on reproductive outcome; however, it is essential to define strict 
criteria for imaging diagnosis and classification of adenomyo-
sis in order to design and then compare homogeneous studies. 
This would allow clinicians to evaluate whether the severity and 
extent of disease have an additional negative effect and deter-
mine the therapeutic options to improve fertility in patients with 
adenomyosis.
Impact on pregnancy outcome
Adenomyosis is considered a reproductive disorder and an 
increasing number of papers are showing that not only fertility 
but also pregnancy outcome is affected. Given late pregnancy out-
comes, an increased risk of preterm birth (PTB) (adjusted odds 
ratio [aOR] 1.84, 95% CI 1.32–4.31) and preterm premature rup-
ture of membranes (aOR 1.98, 95% CI 1.39–3.15) in patients 
with adenomyosis was shown72. These results were confirmed in a 
small cohort of women diagnosed by ultrasound or MRI before 
pregnancy, showing also a significantly higher risk of cesar-
ean delivery (OR 4.5, 95% CI 2.1–9.7), small for gestational age 
(SGA) fetuses (OR 4.3, 95% CI 1.8–10.3), postpartum hemor-
rhage (OR 6.5, 95% CI 2.2–19.0), and fetal malpresentation 
(OR 4.2, 95% CI 1.6–10.8)73. Furthermore, a recent retrospec-
tive case-control study reported that adenomyosis is also associ-
ated with increased risk of second-trimester miscarriage (OR 11.2, 
95% CI 2.2–71.2), pre-eclampsia (OR 21.0, 95% CI 4.8–124.5), 
and placental malposition (OR 4.9, 95% CI 1.4–16.3)74. The type 
of adenomyosis may influence the pregnancy outcome, as shown 
by the higher rates of pregnancy-induced hypertension and uter-
ine infection in patients with diffuse-type adenomyosis than in 
patients with focal-type adenomyosis. In addition, as found in the 
same study, the rates of cervical incompetency increased accord-
ing to the extent of adenomyosis75. Very recently, a prospective 
Japanese nationwide birth cohort study was published, and accord-
ing to results obtained from self-reported questionnaires, ade-
nomyosis was a risk factor for PTB of less than 37 weeks (aOR 
2.49, 95% CI 1.89–3.41), PTB of less than 34 weeks (aOR 1.91, 
95% CI 1.02–3.55), low birth weight of less than 2500 g (aOR 
1.83, 95% CI 1.36–2.45), low birth weight of less than 1500 g (aOR 
2.39, 95% CI 1.20–4.77), and SGA neonates (aOR 1.68, 95% 
CI 1.13–2.51)76.
Concerning the pathogenic mechanisms involved in obstetric 
complications in adenomyosis, the role of inflammation, increased 
myometrial prostaglandin production, altered uterine contrac-
tility, and intrauterine pressure was hypothesized to explain 
the link with PTB77. In adenomyosis, an activation of local and 
systemic inflammatory pathways was shown, influencing the 
decidua–trophoblast interactions early in gestation as well as 
chorion–decidua interactions that could activate mechanisms 
of PTB later in pregnancy77. In regard to the increased rate of 
placenta-related disorders, the defective myometrial spiral artery 
remodeling and deep placentation can be considered to be among 
the major causes of obstetrical syndromes in adenomyosis. 
In fact, alterations in the inner myometrium and in the uterine 
JZ have been well documented12,78. However, further research 
protocols are needed from both the epidemiological and physio- 
pathological point of view. In fact, well-conducted studies may 
be performed only if uniform and shared imaging diagnostic 
criteria and classification are used to make the pre-pregnancy 
diagnosis of adenomyosis. Similarly, the lack of evidence on 
molecular mechanisms leading to obstetric complications in 
adenomyosis should be filled.
Management of adenomyosis
Adenomyosis has a negative impact on women’s quality of life 
in a high percentage of cases because of AUB and pain requiring 
a lifelong management plan through medical or surgical treat-
ment79. The choice depends on the woman’s age, reproductive 
status, and clinical symptoms. However, so far, few clinical stud-
ies focusing on medical or surgical treatment for adenomyosis 
have been performed, and no drugs labelled for adenomyo-
sis are currently available8. Nonetheless, the disease is increas-
ingly diagnosed in young women with reproductive desire, and 
conservative treatments should be preferred.
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The surgical approach remains a controversial subject80, but 
minimally invasive surgical treatments should be performed in 
specific cases, informing the patient about the potential risks in 
case of pregnancy. Conservative surgical options include endome-
trial ablation, hysteroscopic endometrial and adenomyoma 
resection, laparoscopic resection of adenomyosis, high-inten-
sity focused ultrasonography, and uterine artery embolization81. 
However, robust evidence supporting conservative surgical 
treatments of adenomyosis is still lacking.
According to pathogenic mechanisms, several medical hormo-
nal and non-hormonal treatments are used off-label to manage 
pain and bleeding and to improve fertility outcome. The use of 
GnRHa is indicated before fertility treatments to improve the 
chances of pregnancy in infertile women with adenomyosis61, 
and the highest pregnancy rate is reported in those undergoing 
frozen embryo transfer after GnRHa pre-treatment82. In contrast, 
the use of GnRHa for pain and bleeding should be considered 
only for short-term treatment because of menopausal effects.
The use of progestins is supported by the anti-proliferative and 
anti-inflammatory effect and decidualization and then atrophy 
of endometrial tissue, causing a significant reduction in bleed-
ing8. Among progestins, norethisterone acetate (NETA), vaginal 
danazol, and dienogest (DNG) may be considered. Recently, a 
randomized, double-blind, multicenter, placebo-controlled trial 
on DNG, daily administered for 16 weeks in women with aden-
omyosis, showed a significant decrease of pain score in those 
treated83. The results were confirmed in a long-term treatment 
study, demonstrating good tolerability and a reduction in pain and 
higher quality-of-life scores84. The levonorgestrel-releasing 
intrauterine system (LNG-IUS) is also an effective, reversible, 
and long-term treatment used successfully to treat adenomyosis. 
Results show that it reduces menstrual bleeding, pain, and uterine 
volume and has an overall satisfaction of 72%85. However, 
new drugs, such as selective progesterone receptor modulators, 
aromatase inhibitors, valproic acid, and anti-platelet therapy, 
are under development for the treatment of adenomyosis8.
Conclusions
In the last decade, a significant improvement has been achieved 
in understanding and management of adenomyosis. Adenom-
yosis has become a clinical entity rather than just a histological 
diagnosis and it can be identified through non-invasive imag-
ing techniques. An increasing amount of evidence is showing the 
pathogenic mechanisms involved and the potential medical 
treatments. However, there is still the urgent need for a uniform 
and shared diagnostic criteria profile and reporting system, in 
both imaging and histology, in order to identify all of the clini-
cal and imaging phenotypes of adenomyosis. This is the first step 
to share a common language among scientists and clinicians, 
who would share the same diagnostic criteria. This would allow 
clinicians to design and perform methodologically well-conducted 
prospective studies on adenomyosis prevalence, gynecological 
comorbidities, effectiveness of medical or surgical treatments, 
and impact on fertility and pregnancy outcome.
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